Delivery Order SPE2DB22D2206-SPE2DB25FGS53
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of OxyContin ER 10 mg tablets (100-count) valued at $3,143.30. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 7, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of OxyContin ER 10 mg tablets (100-count units) with a ceiling value of $2,098.96. This is a firm fixed price delivery order with an ultimate completion date of August 22, 2025, and represents a non-competitive set-aside contract. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 5, 2025, for the supply of OxyContin ER 10 mg tablets (100-count units) with a contract ceiling value of $1,824.59. This is a firm fixed-price delivery order with an ultimate completion date of May 6, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of OxyContin ER 10 mg tablets in quantities of 100 units. This firm fixed-price delivery order, valued at $1,955.66, is set to be completed by September 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made on a non-set-aside basis, indicating open competitive procurement. This delivery order is...
- The Defense Logistics Agency awarded a $1,026.24 delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for OxyContin ER 10 mg tablets (100-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 23, 2025. The pharmaceutical products will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of OxyContin ER 20 mg tablets (100-count units) with a contract value of $2,783.05. This delivery order represents a firm fixed price, non-set-aside competitive award supporting federal medical procurement needs. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of September 5, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,845.42 on August 5, 2025, for the supply of OxyContin ER 20 mg tablets (100-count units). This is a firm fixed-price, non-set-aside contract with a completion date of August 6, 2025, and performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order was issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for OxyContin ER 10 mg tablets (100-count units) on September 2, 2025, with a ceiling value of $2,259.98 and an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of OxyContin ER 10 mg tablets (100-count units) with a contract ceiling value of $2,030.33. This non-set-aside award utilizes firm fixed price pricing and is scheduled for completion by September 15, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 22, 2025, for the supply of OxyContin ER 40 mg tablets (100-count packages) at a ceiling value of $8,696.13. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competitive procurement. The order is scheduled for ultimate completion on May 23, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility, where...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FGS53Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of OxyContin ER 10 mg tablets (100-count units) with a ceiling value of $1,785.50. This is a firm fixed price delivery order with an ultimate completion date of April 25, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order supports the Defense Logistics Agency's Medical Supply Chain operations, which provide pharmaceutical products and medical supplies to military and veteran healthcare systems. AmerisourceBergen's pharmaceutical distribution capabilities enable the company to serve as a critical vendor for federal medical procurement, supplying a comprehensive range of therapeutics including pain management medications, specialty drugs, and other healthcare commodities. The DLA's Pharmaceutical Prime Vendor Global Program Generation V initiative, under which this broader contract vehicle operates, is designed to leverage multiple contractors across separate regions to ensure reliable pharmaceutical support to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 4/24/25 |